Overview

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Status:
Unknown status

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting tyrosine kinase activation. This is a randomized, controlled, open-Label, multicenter, phase Ⅱ clinical trial of nimotuzumab plus Docetaxel and Capecitabine（TX）versus Docetaxel and Capecitabine（TX）as first-line treatment in patients with recurrent/metastatic triple negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Collaborator:

Biotech Pharmaceutical Co., Ltd.

Treatments:

Capecitabine
Docetaxel
Nimotuzumab